We are live on ! Find out more
EA

Emerald Advisers Portfolio holdings

AUM $3.16B
1-Year Est. Return 109.58%
This Fund
S&P 500
This Quarter Est. Return
+10.94%
1 Year Est. Return
+109.58%
3 Year Est. Return
+352.93%
5 Year Est. Return
+451.34%
10 Year Est. Return
+3,577.15%
AUM
$2.09B
AUM Growth
+$15.8M
Cap. Flow
-$86M
Cap. Flow %
-4.12%
Top 10 Hldgs %
18.08%
Holding
266
New
20
Increased
45
Reduced
134
Closed
56

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$18.8M
2
TENB icon
Tenable Holdings
TENB
+$16.8M
3
LIVN icon
LivaNova
LIVN
+$14M
4
FN icon
Fabrinet
FN
+$13.9M
5
ICUI icon
ICU Medical
ICUI
+$11.8M

Top Sells

Rank Stock Value
1
ACDC icon
ProFrac Holding
ACDC
+$26.1M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$21.4M
3
CUBI icon
Customers Bancorp
CUBI
+$16M
4
MTSI icon
MACOM Technology Solutions
MTSI
+$14.6M
5
PRFT
Perficient Inc
PRFT
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 31.06%
2 Technology 16.79%
3 Industrials 15.69%
4 Consumer Discretionary 14.06%
5 Financials 6.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
201
DexCom
DXCM
$27.6B
$257K 0.01%
2,212
-2,452
-53% -$274K
EXPE icon
202
Expedia Group
EXPE
$31.2B
$249K 0.01%
2,570
-1,606
-38% -$168K
OCUL icon
203
Ocular Therapeutix
OCUL
$1.86B
$241K 0.01%
45,717
-919,524
-95% -$4.37M
WSM icon
204
Williams-Sonoma
WSM
$26.7B
$239K 0.01%
3,930
-24
-0.6% -$1.5K
ILMN icon
205
Illumina
ILMN
$29.4B
$236K 0.01%
1,043
-2,153
-67% -$441K
TROW icon
206
T. Rowe Price
TROW
$25B
$232K 0.01%
2,055
-12
-0.6% -$1.37K
CIEN icon
207
Ciena
CIEN
$55.3B
$231K 0.01%
+4,392
New +$219K
AZTA icon
208
Azenta
AZTA
$1.26B
$213K 0.01%
4,765
+1,817
+62% +$90K
BLCO icon
209
Bausch + Lomb
BLCO
$5.77B
$206K 0.01%
+11,850
New +$201K
JSDA
210
DELISTED
JONES SODA CO
JSDA
$11.7K ﹤0.01%
46,624
– –
ACDC icon
211
ProFrac Holding
ACDC
$771M
– –
-1,036,375
Closed -$26.1M
ADBE icon
212
Adobe
ADBE
$89.5B
– –
-79
Closed -$26.6K
ADEA icon
213
Adeia
ADEA
$2.86B
– –
-4
Closed -$39
AMT icon
214
American Tower
AMT
$77.7B
– –
-175
Closed -$37.1K
ANSS
215
DELISTED
Ansys
ANSS
– –
-64
Closed -$15.5K
AR icon
216
Antero Resources
AR
$10.9B
– –
-13,345
Closed -$414K
ARKG icon
217
ARK Genomic Revolution ETF
ARKG
$1.51B
– –
-1,696
Closed -$47.9K
ATEX icon
218
Anterix
ATEX
$1.83B
– –
-1,100
Closed -$35.4K
ATI icon
219
ATI
ATI
$27B
– –
-2,920
Closed -$87.2K
BAC icon
220
Bank of America
BAC
$435B
– –
-1,200
Closed -$39.7K
BMRA icon
221
Biomerica
BMRA
$4.88M
– –
-2,375
Closed -$63.6K
BBBY
222
Bed Bath & Beyond
BBBY
$473M
– –
-5,995
Closed -$106K
C icon
223
Citigroup
C
$222B
– –
-6
Closed -$270
CRM icon
224
Salesforce
CRM
$134B
– –
-200
Closed -$26.5K
CSCO icon
225
Cisco
CSCO
$450B
– –
-723
Closed -$34.4K
7 8
9
10 11

Similar funds

FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
CVA
Ceredex Value Advisors Orlando, Florida $3.18B AUM 35.23% 1-Year Est. Return
DWP
Daymark Wealth Partners Cincinnati, Ohio $3.18B AUM 23.46% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FAM
Foxhaven Asset Management Charlottesville, Virginia $3.19B AUM 12.34% 1-Year Est. Return

Emerald Advisers's Q1 2023 Portfolio in Review

As of Q1 2023, Emerald Advisers held 266 positions worth $2.09B, up 0.76% from $2.07B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Emerald Advisers withdrew a net $86M in Q1 2023, closing 56 positions and reducing 134 holdings. Its most notable exit was ProFrac Holding, an estimated $26.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Industrials.

Against the trend, Emerald Advisers opened a new position in LivaNova worth $12.1M.

  • Emerald Advisers's largest Q1 2023 buy was LivaNova: 277,388 shares worth $12.1M.
  • Emerald Advisers added most to Madrigal Pharmaceuticals in Q1 2023, an estimated $18.8M increase.
  • Emerald Advisers's biggest Q1 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $21.4M.
  • Emerald Advisers fully exited ProFrac Holding in Q1 2023, selling an estimated $26.1M.
  • Emerald Advisers's ten largest holdings make up 18% of its $2.09B portfolio in Q1 2023.
  • Emerald Advisers opened 20 new positions and closed 56 in Q1 2023.
  • Emerald Advisers's portfolio value rose 0.76% quarter-over-quarter to $2.09B.

Based on Emerald Advisers's 13F filing for Q1 2023, filed 4 May 2023.